Spots Global Cancer Trial Database for Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
Official Title: Phase II Study of Cetuximab Combined With Intensity Modulated Radiotherapy (IMRT) and Concurrent Chemotherapy of Cisplatin in Nasopharyngeal Carcinoma
Study ID: NCT00700440
Conditions
Interventions
Study Description
Brief Summary: This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact Details
Name: Tai-xiang Lu, M.D.
Affiliation: Departments of Radiation Oncology, Cancer Center, Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR
Name: Tong-yu Lin, M.D., PhD
Affiliation: Departments of Chemotherapy, Cancer Center, Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
